244 related articles for article (PubMed ID: 26844560)
21. Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD.
Ma C; Wu W; Lin R; Ge Y; Zhang C; Sun S; Cong Y; Li X; Liu Z
J Crohns Colitis; 2019 Mar; 13(4):510-524. PubMed ID: 30395204
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD6 for the treatment of experimental autoimmune uveitis.
Zhang L; Li Y; Qiu W; Bell BA; Dvorina N; Baldwin WM; Singer N; Kern T; Caspi RR; Fox DA; Lin F
J Autoimmun; 2018 Jun; 90():84-93. PubMed ID: 29472120
[TBL] [Abstract][Full Text] [Related]
23. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.
Aira LE; Hernández P; Prada D; Chico A; Gómez JA; González Z; Fuentes K; Viada C; Mazorra Z
MAbs; 2016; 8(1):187-95. PubMed ID: 26466969
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.
Budamakuntla L; Shree-Lakshmi HV; Bansal A; Venkatarayaraju SK
Psoriasis (Auckl); 2019; 9():19-27. PubMed ID: 31119094
[TBL] [Abstract][Full Text] [Related]
25. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues.
Saifullah MK; Fox DA; Sarkar S; Abidi SM; Endres J; Piktel J; Haqqi TM; Singer NG
J Immunol; 2004 Nov; 173(10):6125-33. PubMed ID: 15528349
[TBL] [Abstract][Full Text] [Related]
26. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease.
Montero E; Falcon L; Morera Y; Delgado J; Amador JF; Perez R
Autoimmunity; 1999; 29(2):155-6. PubMed ID: 10433078
[No Abstract] [Full Text] [Related]
27. Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
Pai G; Pai AH
Case Rep Dermatol; 2017; 9(2):141-145. PubMed ID: 29033818
[TBL] [Abstract][Full Text] [Related]
28. CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses.
Brown MH
Curr Drug Targets; 2016; 17(6):619-29. PubMed ID: 26302795
[TBL] [Abstract][Full Text] [Related]
29. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation.
Osorio LM; Garcia CA; Jondal M; Chow SC
Cell Immunol; 1994 Mar; 154(1):123-33. PubMed ID: 7509726
[TBL] [Abstract][Full Text] [Related]
30. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
31. CD6 recognizes the neural adhesion molecule BEN.
Skonier JE; Bowen MA; Aruffo A; Bajorath J
Protein Sci; 1997 Aug; 6(8):1768-70. PubMed ID: 9260290
[TBL] [Abstract][Full Text] [Related]
32. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC; Torres-Moya R; Reyes G; Molinero C; Prada D; Lopez AM; Hernandez IM; Hernandez MV; Martinez JP; Hernandez X; Casaco A; Ramos M; Avila Y; Barrese Y; Montero E; Hernandez P
Results Immunol; 2012; 2():204-11. PubMed ID: 24371585
[TBL] [Abstract][Full Text] [Related]
33. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
Saavedra D; Añé-Kourí AL; Sánchez N; Filgueira LM; Betancourt J; Herrera C; Manso L; Chávez E; Caballero A; Hidalgo C; Lorenzo G; Cepeda M; Valenzuela C; Ramos M; León K; Mazorra Z; Crombet T
Immun Ageing; 2020 Nov; 17(1):34. PubMed ID: 33292350
[TBL] [Abstract][Full Text] [Related]
34. Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation.
Osorio LM; Ordonez C; Garcia CA; Jondal M; Chow SC
Cell Immunol; 1995 Nov; 166(1):44-52. PubMed ID: 7585980
[TBL] [Abstract][Full Text] [Related]
35. Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens.
Kato Y; Tanaka Y; Hayashi M; Okawa K; Minato N
J Immunol; 2006 Jul; 177(2):877-84. PubMed ID: 16818742
[TBL] [Abstract][Full Text] [Related]
36. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions.
Bowen MA; Aruffo AA; Bajorath J
Proteins; 2000 Aug; 40(3):420-8. PubMed ID: 10861932
[TBL] [Abstract][Full Text] [Related]
37. Dynamic coupling of ALCAM to the actin cortex strengthens cell adhesion to CD6.
Te Riet J; Helenius J; Strohmeyer N; Cambi A; Figdor CG; Müller DJ
J Cell Sci; 2014 Apr; 127(Pt 7):1595-606. PubMed ID: 24496453
[TBL] [Abstract][Full Text] [Related]
38. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
[TBL] [Abstract][Full Text] [Related]
39. Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.
Budamakuntla L; Madaiah M; Sarvajnamurthy S; Kapanigowda S
Clin Exp Dermatol; 2015 Mar; 40(2):152-5. PubMed ID: 25495868
[TBL] [Abstract][Full Text] [Related]
40. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site.
Whitney GS; Starling GC; Bowen MA; Modrell B; Siadak AW; Aruffo A
J Biol Chem; 1995 Aug; 270(31):18187-90. PubMed ID: 7543097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
